Background: Developing new antibacterial and antiviral drugs are considered a significant issue due to the emergence and spread of resistant strains of microorganisms. The COVID-19 pandemic has dramatically increased the need for new broad-spectrum anti-infective agents.
Objective: This experimental study aimed to investigate the antibacterial and phagocytic properties of silver-interferon preparation. The combination of properties of complex drugs makes them promising for treating drug-resistant infections and bacterial complications of viral diseases.
Methods: The antibacterial effect of the silver-interferon platform was investigated by agar diffusion and serial dilution methods. The drug's effect on the functional activity of phagocytes was studied on human neutrophils in a Staphylococcus aureus uptake test.
Results: Investigations have shown that the silver-interferon complex possesses a bactericidal mechanism of action against tested bacterial strains, including Streptococcus pneumonia, Salmonella enteritidis, Staphylococcus aureus, Escherichia coli. Streptococcus pneumonia was the most susceptible bacterial target for the tested complex, with a growth inhibition zone of 12±0.6 mm and a minimal bactericidal concentration of 0.08 mg/ml. A slight stimulating action of the drug in relation to the activity of phagocytes was revealed.
Conclusion: Silver-interferon has proved as a prospective anti-infective drug with a wide range of activities.
[http://dx.doi.org/10.1002/1097-4636(20001215)52:4<662:AID-JBM10>3.0.CO;2-3] [PMID: 11033548]
[http://dx.doi.org/10.1186/s12951-015-0120-6] [PMID: 26438142]
[http://dx.doi.org/10.1186/s12989-018-0283-z] [PMID: 30518385]